Semaglutide and dapagliflozin synergistically prevent cancer therapy-related cardiac dysfunction in hyperglycemic conditions

4 April 2025 (13:00 - 13:45)
Organised by: Logo
Congress Presentation Part of: Cardiovascular protection in patients with cancer Cardio-Oncology EAPC Premium Access ESC Preventive Cardiology 2025 European Association of Preventive Cardiology (EAPC)

ESC 365 is supported by

ESC 365 is supported by